TABLE 4.

Correlation and expression analysis of HAT enzymes and prediction of therapeutic axis In GBM.

E3 ligase	E2 conjugating enzymes	Potential K residue position	Histone acetyltransferases (HATs) enzymes						Therapeutic axis	Loss of acetylation site
		Confidence score >2.5	CREBBP	EP300	HAT1	KAT2A	KAT2B	KAT5
VHL	UBE2E1	43	-	-	$\surd$	$\chi$	-	-	HAT1-UBE2E1(K43)-VHL	No
	UBE2H	8	-	-	$\surd$	-	-	-	HAT1-UBE2H(K8)-VHL	Yes
		$52$	-	-	$\surd$	-	-	-	HAT1-UBE2H(K52)-VHL	No
	UBE2J2	$64$	-	-	$\surd$	-	-	-	HAT1-UBE2J2(K64)-VHL	No
		$88$	-	-	$\surd$	-	-	$\chi$	HAT1-UBE2J2(K88)-VHL	No
GNB2L1	UBE2C	18	-	$\chi$	$\surd$	-	-	-	HAT1-UBE2C(K18)-GNB2L1	No
		$33$	-	-	-	-	$\chi$	-	-	Yes
	UBE2J2	$64$	-	-	$\surd$	-	-	-	HAT1-UBE2J2(K64)-GNB2L1	No
		$88$	-	-	$\surd$	-	-	$\chi$	HAT1-UBE2J2(K88)-GNB2L1	No
	UBE2S	$198$	-	-	-	$\chi$	-	-	-	Yes
		$210$	-	-	-	$\chi$	-	-	-	Yes
		$211$	-	-	$\surd$	$\chi$	$\chi$	-	HAT1-UBE2S(K211)-GNB2L1	Yes
		$215$	-	-	-	$\chi$	-	-	-	Yes
		$216$	$\chi$	-	-	$\chi$	$\chi$	-	-	Yes

^⁃ Lysine residues marked in blue are novel and have not been previously documented in the literature for acetylation modification in GBM, patients.

^⁃ p-value≤0.05: significant; p-value>0.05; ns: not significant.

^⁃√: signifies HAT1 enzymes expression is upregulated, with the significant positive correlation between HAT1 and Ube2E1, Ube2H and Ube2C, Ube2J2, Ube2S.

^⁃ χ: signifies KAT2A enzyme expression is downregulated, with a not significant association between KAT2A and Ube2E1, Ube2A.

^⁃ χ: signifies CREBBP, EP300, KAT2B, and KAT5 enzyme expression is not significant, with no significant association between CREBBP, and Ube2S; EP300 and Ube2C; KAT2B and Ube2C, Ube2S; KAT5 and Ube2J2.

^⁃ The pink rectangle box represents the first proposed therapeutic axis in GBM.

^⁃ The brown rectangle box represents the second proposed therapeutic axis in GBM.